How Albuterol Works in a COPD Patient
How Albuterol Works
Normally, air travels through the mouth, pass the oropharynx, down the trachea, to the small air passages, and finally to the alveoli. The alveoli are small, inflated, balloon-shaped structures where oxygen is exchanged for carbon dioxide, thus sustaining life. This exchange is interrupted when there is obstruction anywhere along this pathway. Causes of airway obstruction include excess production of mucous, smooth muscle contractions, inflammation, and destruction of the airways themselves. COPD is an umbrella term given to this group of diseases.
If you are experiencing serious medical symptoms, seek emergency treatment immediately.
The Global Initiative on Chronic Obstructive Pulmonary Disease -- GOLD -- , further defines COPD as chronic limitations to airflow due to obstruction that are partially reversible and more than likely progressive in nature. Asthma, emphysema, and chronic bronchitis are all considered chronic obstructive diseases. Patients may have mild to severe disease occasionally experiencing exacerbations or worsening of symptoms. Stable COPD patients may quickly advance to unstable due to infections, allergens, exercise, stress, chemical exposure, or trauma. This is when emergency relief drugs like Albuterol are necessary to alleviate symptoms during this time. Symptoms may include, difficulty breathing, wheezing, coughing, retention of carbon dioxide, among others.
- Normally, air travels through the mouth, pass the oropharynx, down the trachea, to the small air passages, and finally to the alveoli.
- Stable COPD patients may quickly advance to unstable due to infections, allergens, exercise, stress, chemical exposure, or trauma.
The Chemical Process of Albuterol
How Does Albuterol Sulfate Work?
Learn More
Albuterol belongs to a class of drugs called beta-agonist. While other drugs are used in the relief of COPD, each drug has a specific role. A beta-agonist's major role is to work to correct lung obstruction due to smooth muscle constriction. Its mechanism of action is at the cellular level. Albuterol binds with beta2-adrenergic receptors in the lungs' system, causing smooth muscle relaxation and allowing the airway passages and alveoli to open up. This allows unobstructed air flow leading to a subsequent relief of symptoms.
Combining with other drugs, beta-agonists work to prevent the release of inflammatory products, improve clearance of mucous and prevent the leakage of immune response cells into airways.
- Albuterol belongs to a class of drugs called beta-agonist.
- Combining with other drugs, beta-agonists work to prevent the release of inflammatory products, improve clearance of mucous and prevent the leakage of immune response cells into airways.
How Albuterol Is Administered
Delivering the drug to the lungs as efficiently as possible is essential. B-agonist come in different preparations. Albuterol can be delivered by mouth or by inhalation. As an inhaled bronchodilator, the drug is delivered to the lungs as a fine mist from a metered dose inhaler -- MDI.
Patient response time is also a consideration when using a drug. When patients with COPD are in emergent need of relief, they need a drug with a quick response time. Albuterol works to help relieve symptoms in a matter of minutes.
Albuterol stays in the blood stream for up to 8 hours. Therefore, it is considered a short-acting drug used in the short-term management of COPD. It is both fast and potent, helping to save lives.
- Delivering the drug to the lungs as efficiently as possible is essential.
- Therefore, it is considered a short-acting drug used in the short-term management of COPD.
Related Articles
References
- Merck
- NIH: National Heart, Lung, and Blood Institute. COPD.
- InformedHealth. Chronic obstructive pulmonary disease (COPD). Updated March 14, 2019.
- Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18(1):67. doi:10.1186/s12931-017-0548-3
- Sajadi SMA, Majidi A, Abdollahimajd F, Jalali F. Relationship between Dyspnea Descriptors and Underlying Causes of the Symptom; a Cross-sectional Study. Emerg (Tehran). 2017;5(1):e62.
- Ramos FL, Krahnke JS, Kim V. Clinical issues of mucus accumulation in COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:139–150. doi:10.2147/COPD.S38938
- Lesan A, Lamle AE. Short review on the diagnosis and treatment of bronchiectasis. Med Pharm Rep. 2019;92(2):111–116. doi:10.15386/cjmed-1060
- Moua T, Wood K. COPD and PE: a clinical dilemma. Int J Chron Obstruct Pulmon Dis. 2008;3(2):277–284.
- Yohannes AM, Alexopoulos GS. Depression and anxiety in patients with COPD. Eur Respir Rev. 2014;23(133):345–349. doi:10.1183/09059180.00007813
- Quint J. The Relationship between COPD and Cardiovascular Disease. Tanaffos. 2017;16(Suppl 1):S16–S17.
- Sandelin M, Mindus S, Thuresson M, et al. Factors associated with lung cancer in COPD patients. Int J Chron Obstruct Pulmon Dis. 2018;13:1833–1839. doi:10.2147/COPD.S162484
- Han MK, Dransfield MT, Martinez FJ. Chronic Obstructive Pulmonary Disease: Definition, Clinical Manifestations, Diagnosis, and Staging. UpToDate. Updated January 11, 2018.
- Kasper DL, Fauci AS, Hauser SL. Harrison's Principles of Internal Medicine. New York: McGraw Hill Education; 2015.
- Mayo Clinic. COPD: Symptoms & Causes. Mayo Clinic Staff. Updated August 11, 2017.
- Miravitilles M, Ribera A. Understanding the Impact of Symptoms on the Burden of COPD. Respiratory Research. 2017;18(1):67. doi:10.1186/s12931-017-0548-3.
- National Heart, Lung, and Blood Institute. COPD. National Institute of Health. U.S. Health and Human Services.
Writer Bio
Dr. Deleshia Kinney received her M.D. from Southern Illinois University School of Medicine. She began writing professionally when she started her own medical marketing and consulting firm. Since then she has been providing quality health care consulting, publications, and presentations to community health organizations including the American Cancer Society, Urban League, Illinois Public Health Association, and Illinois Department of Public Health.